Arax Advisory Partners’s Neurocrine Biosciences NBIX Stock Holding History

Arax Advisory Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.07M	Buy	24,261 +22,829	+1,594%	+$3.39M	0.03%	551
2026 Q1	$189K	Buy	1,432 +1,051	+276%	+$139K	0.01%	1105
2025 Q4	$54K	Sell	381 -39,953	-99%	-$5.79M	﹤0.01%	1569
2025 Q3	$5.66M	Buy	40,334 +40,209	+32,167%	+$5.45M	0.08%	204
2025 Q2	$15.7K	Sell	125 -5	-4%	-$573	﹤0.01%	1764
2025 Q1	$14.4K	Sell	130 -404	-76%	-$51.2K	﹤0.01%	1449
2024 Q4	$72.9K	Sell	534 -248	-32%	-$30.7K	﹤0.01%	780
2024 Q3	$90.1K	Hold	782	–	–	0.01%	525
2024 Q2	$108K	Buy	782 +739	+1,719%	+$101K	0.01%	459
2024 Q1	$5.93K	Hold	43	–	–	﹤0.01%	870
2023 Q4	$5.67K	Sell	43 -3	-7%	-$345	﹤0.01%	860
2023 Q3	$5.18K	Buy	46 +9	+24%	+$948	﹤0.01%	868
2023 Q2	$3.49K	Sell	37 -9	-20%	-$879	﹤0.01%	934
2023 Q1	$4.66K	Hold	46	–	–	﹤0.01%	870
2022 Q4	$5.49K	Hold	46	–	–	﹤0.01%	771
2022 Q3	$5K	Buy	46 +9	+24%	+$913	﹤0.01%	811
2022 Q2	$4K	Hold	37	–	–	﹤0.01%	833
2022 Q1	$3K	Buy	+37	New	+$3.14K	﹤0.01%	890

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arax Advisory Partners's NBIX Position: Q2 2026 in Review

Arax Advisory Partners increased its Neurocrine Biosciences (NBIX) stake by 1,594% in Q2 2026, buying an estimated $3.39M and bringing the position to 24,261 shares worth $4.07M. The position accounts for 0.03% of the portfolio, ranked #551.

Arax Advisory Partners first reported a position in NBIX in Q1 2022 and has held it in 18 quarters since. The position peaked at $5.66M in Q3 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Arax Advisory Partners held 24,261 shares of Neurocrine Biosciences worth $4.07M as of Q2 2026.
Arax Advisory Partners bought 22,829 Neurocrine Biosciences shares in Q2 2026, an estimated $3.39M.
Neurocrine Biosciences made up 0.03% of Arax Advisory Partners's portfolio in Q2 2026, its #551 holding.
Arax Advisory Partners first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 18 quarters since.
Arax Advisory Partners's Neurocrine Biosciences position peaked at $5.66M in Q3 2025.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.